




PHARMACEUTICAL 2020

RELMADA THERAPEUTICS INC.
Rank 289 of 358





RealRate

PHARMACEUTICAL 2020

RELMADA THERAPEUTICS INC. Rank 289 of 358



The relative strengths and weaknesses of RELMADA THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RELMADA THERAPEUTICS INC. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of RELMADA THERAPEUTICS INC. is the variable Net Income, reducing the Economic Capital Ratio by 165% points.

The company's Economic Capital Ratio, given in the ranking table, is -66%, being 102% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	9,984
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,606
Liabilities, Non-Current	0
Other Assets	228
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,590
Other Revenues	0
Property and Equipment	7.2
Research and Development	7,025
Selling, General and Administrative Expense	5,703

Output Variable	Value in 1000 USD
Assets	10,220
Liabilities	2,606
Expenses	12,728
Revenues	0
Stockholders Equity	7,613
Net Income	-17,318
Comprehensive Net Income	-17,318
Economic Capital Ratio	-66%